Summary: Adoptive leukaemia symptoms immunoassay in the form of a transplant allergenic hematologist stem cell transplantation (HSBC allow) is a treatment modality for acute and chronic leukemia, which has been in practice for several decades. Disadvantages include transplant toxicity conditioning treatments of chemotherapy radiation therapy, additional toxicity of VD, and the dependence of donor leukaemia symptoms human leukocyte antigen identified appropriate.
New forms with greater specificity of the donor cells to tumor cells, in addition to the treatments that require the graft to the anti tumor disease reduces the risk of the graft against the host can effect and a higher graft versus leukemia response. Without the need for grafting, leukaemia symptoms or at least in the absence of a condition 100% grafting conditioning regimens can be minimized. Three methods of adoptive immunoassay that may offer some advantages over the traditional transplantation are donor infusions DALI, the receptor cells of the T cell antigen modified chimeric (T CHP) and cellular immunoassay.
DD and cell therapy consists of the leukaemia symptoms receptor transfusion donor T cells in an unmodified form. Alternatively, donor T cells may be modified by the addition of chimeric antigen receptors led to the specific destruction of the tumor cell antigen. Significant responses and survival benefit has been reported with these terms. Here, we review the mechanisms of these immune therapies adoptive latest, clinical indications for the use and leukaemia symptoms possible future directions.